28.56 USD
↗ 0.46 (1.64%)AT CLOSE (11:59 AM EDT)
Zymeworks Inc.
ZYMENASDAQ • USD
29.00
↗ 0.44 (1.54%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
29.00
↗ 0.44 (1.54%)
Market: CLOSED
Open?$27.93
High?$29.75
Low?$27.93
Prev. Close?$28.10
Volume?950.2K
Avg. Volume?599.2K
VWAP?$28.92
Rel. Volume?1.59x
Bid / Ask
Bid?$28.00 × 900
Ask?$30.00 × 300
Spread?$2.00
Midpoint?$29.00
Valuation & Ratios
Market Cap?2.1B
Shares Out?73.7M
Float?47.1M
Float %?63.0%
P/E Ratio?N/A
P/B Ratio?7.90
EPS?-$1.09
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?5.88Strong
Quick Ratio?5.88Strong
Cash Ratio?0.97Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?7.90FAIR▾
P/S?20.03HIGH▾
P/FCF?N/A▾
EV/EBITDA?-24.5CHEAP▾
EV/Sales?19.64HIGH▾
Returns & Efficiency
ROE?-30.2%WEAK▾
ROA?-23.4%WEAK▾
Cash Flow & Enterprise
FCF?$-34526000
Enterprise Value?$2.1B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Employees
264
Market Cap
2.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2017-04-28
Address
108 PATRIOT DRIVE, SUITE A
MIDDLETOWN, DE 19709
Phone: 302-274-8744
MIDDLETOWN, DE 19709
Phone: 302-274-8744